Gardasil approved for more cancer treatments

Gardasil, the controversial vaccine manufactured by Merck Inc., has now been approved to prevent more cancers by the Food and Drug Administration.

The FDA approved Gardasil to prevent the onset of some types of vulva and vaginal cancers in girls and women from 9 to 26.

The vaccine which has been linked to numerous, and some severe side effects is already approved to prevent certain strains of the human papillomoavirus (HPV). Some strains of the HPV virus have been known to also cause vulvar and vaginal cancers.

Such cancers are rare, but the FDA felt compelled to approve Merck’s request.

Gardasil first gained FDA approval in 2006 and since then has been a source of much controversy, including being linked to the death of one woman who received the vaccine treatment.

The vaccine has been mandated in some U.S. states, meaning all girls are to have it much like they would the early childhood vaccines.

This, combined with mountains of positive press, have garnered Merck millions in profits in just a few short years.

Merck, since gaining the initial FDA approval, has pushed to have it be a vaccination treatment for other types of cancer, including men.

Some girls and women who get the vaccine report swelling and tenderness at the injection site, and a growing number of women also report fainting following the shot.

Merck is criticized for rushing Gardasil to the market when it was realized a clinical trial was only conducted for two years prior to it being available to the U.S. public.